Oppenheimer Holdings, Inc. set a $85.00 price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts have also recently commented on NBIX. Cowen and Company reissued an outperform rating and set a $65.00 target price (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Deutsche Bank AG reissued a buy rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Citigroup Inc. reissued a buy rating and set a $79.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. BidaskClub raised shares of Neurocrine Biosciences from a hold rating to a buy rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the company an outperform rating in a research report on Friday, August 4th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The company has an average rating of Buy and an average price target of $78.88.
Neurocrine Biosciences (NASDAQ:NBIX) traded down $0.02 during trading hours on Tuesday, reaching $72.28. 866,071 shares of the company were exchanged, compared to its average volume of 1,122,800. Neurocrine Biosciences has a 12 month low of $37.35 and a 12 month high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analysts’ expectations of $29.38 million. During the same period in the previous year, the company earned ($0.43) EPS. equities analysts anticipate that Neurocrine Biosciences will post -1.74 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Oppenheimer Holdings, Inc. Reiterates $85.00 Price Target for Neurocrine Biosciences, Inc. (NBIX)” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://stocknewstimes.com/2017/11/17/oppenheimer-holdings-inc-reiterates-85-00-price-target-for-neurocrine-biosciences-inc-nbix.html.
In other news, insider Christopher Flint Obrien sold 52,817 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total value of $3,036,977.50. Following the sale, the insider now owns 101,790 shares in the company, valued at $5,852,925. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dimitri E. Grigoriadis sold 30,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the insider now owns 77,691 shares in the company, valued at approximately $5,794,194.78. The disclosure for this sale can be found here. Insiders sold 150,710 shares of company stock worth $9,758,593 in the last quarter. Company insiders own 4.80% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System increased its stake in shares of Neurocrine Biosciences by 1.5% in the third quarter. California Public Employees Retirement System now owns 181,900 shares of the company’s stock worth $11,147,000 after acquiring an additional 2,600 shares during the period. Davidson Kempner Capital Management LP increased its stake in shares of Neurocrine Biosciences by 50.8% in the third quarter. Davidson Kempner Capital Management LP now owns 119,300 shares of the company’s stock worth $7,311,000 after acquiring an additional 40,200 shares during the period. Crestline Management LP increased its stake in shares of Neurocrine Biosciences by 41.1% in the third quarter. Crestline Management LP now owns 63,029 shares of the company’s stock worth $3,862,000 after acquiring an additional 18,371 shares during the period. Perceptive Advisors LLC increased its stake in shares of Neurocrine Biosciences by 33.9% in the third quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock worth $293,629,000 after acquiring an additional 1,214,000 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after acquiring an additional 140,639 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.